Clinical Trials Logo

HIV-1 Infection clinical trials

View clinical trials related to HIV-1 Infection.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05769569 Withdrawn - HIV-1-infection Clinical Trials

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

RV582
Start date: September 1, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I, randomized, open-label trial to investigate the safety of VRC07-523LS, PGDM1400LS and N-803 in combination with Ad26.Mos4.HIV, MVA-Bavarian Nordic (BN)-HIV and A244d11gp120/ALFQ vaccination, and the impact on time to sustained viral rebound of ≥1000 copies/mL for 4 consecutive weeks during analytic treatment interruption (ATI) in people living with human immunodeficiency virus-1 (HIV-1, PLWH) who initiated antiretroviral therapy (ART) during acute HIV-1 infection (AHI).

NCT ID: NCT05700630 Withdrawn - HIV-1-infection Clinical Trials

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Start date: July 15, 2024
Phase: Phase 1
Study type: Interventional

This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid tissue of HIV-infected individuals receiving standard of care (SOC) antiretroviral therapy (ART). As this is an early 1st in human study and the 1st for HIV-infected individual, the safety of FT538 is confirmed prior to the addition of oral vorinostat to explore the concept of "Kick and Kill".

NCT ID: NCT05295394 Withdrawn - HIV-1 Infection Clinical Trials

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study

PADDLE184V
Start date: May 22, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of dual therapy with 3TC and DTG as initial therapy among naïve HIV patients with a documented M184V mutation.

NCT ID: NCT05156658 Withdrawn - HIV-1-infection Clinical Trials

Pharmacokinetic Interactions of ENG Subdermal Implants With Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)

Start date: January 1, 2024
Phase: Phase 4
Study type: Interventional

The purpose of this pharmacokinetic (PK) trial is to evaluate whether the ENG implant, a long-acting birth control method, is tolerable and effective for adults with HIV who are taking long-acting cabotegravir (CAB-LA) and long-acting rilpivirine (RPV-LA). Access to safe and effective birth control for adults with HIV is important because it may result in fewer infants exposed to HIV in the womb or born with HIV. Researchers believe that people of childbearing potential need access to birth control options that do not need to be negotiated with a partner.

NCT ID: NCT04041362 Withdrawn - HIV-1 Infection Clinical Trials

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

Start date: April 2020
Phase: Phase 2
Study type: Interventional

This study assess the safety, tolerability, and efficacy in reducing viral load and proviral DNA of UB-421 administered as an add-on to the ART in ART-experienced viremic HIV-1 subjects.

NCT ID: NCT03834909 Withdrawn - Pregnancy Clinical Trials

Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)

Start date: April 2022
Phase: Phase 1
Study type: Interventional

This trial is a prospective, multi-center, randomized comparison study of 2 Pre-Exposure Prophylaxis (PrEP) pharmacokinetic (PK) dosing regimens from 1st trimester through 12 weeks following delivery (postpartum) to achieve study objectives which include PK, safety monitoring for maternal and fetal/infant safety signals, and adherence.

NCT ID: NCT03813979 Withdrawn - HIV-1-infection Clinical Trials

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.

POLO
Start date: November 15, 2020
Phase: Phase 4
Study type: Interventional

This is an open-label, parallel-group, nonrandomized, multi-centre, phase-IV, single dose trial in 8 HIV-seronegative subjects with severe hepatic impairment and 8 matched controls to assess the pharmacokinetics of a single dose of 50mg of dolutegravir in subjects with severe hepatic impairment.

NCT ID: NCT03549689 Withdrawn - HIV/AIDS Clinical Trials

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

ReNew
Start date: August 1, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, randomized pilot study to assess the effect on bone mineral density (BMD) of a switch from a tenofovir alafenamide-containing antiretroviral regimen to dolutegravir/lamivudine vs. a continuation of the tenofovir alafenamide-containing regimen.

NCT ID: NCT03149211 Withdrawn - HIV-1 Infection Clinical Trials

To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

Start date: April 1, 2025
Phase: Phase 3
Study type: Interventional

The purpose of this phase III study is to evaluate the efficacy, safety and tolerability of UB-421 monotherapy in suppressing viral rebound in HIV-1 infected adults undergoing antiretroviral treatment interruption.

NCT ID: NCT03118661 Withdrawn - HIV-1-infection Clinical Trials

Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant

Start date: March 19, 2018
Phase: Phase 1
Study type: Interventional

The goal of this proposal is to determine the effect of maraviroc when it has been a part of the antiretroviral (ART) regimen given immediately after allogeneic hematopoietic cell transplant (allo-HCT) for HIV-1 infected participants who have a hematopoietic malignancy or other underlying disorder requiring an allogeneic transplant. Maraviroc has been given in practice to alleviate symptoms of graft vs. host disease (GvHD). Given its mechanism of action, it may also have an effect on the reservoir size of HIV-1 in infected patients. This study will inform potential future studies, evaluating the effect of this approach on the incidence and severity of GvHD, and determining its effect on HIV-1 reservoir.